A recently published review outlines the approach to the treatment of venous thromboembolism in pregnancy using patient case studies from their clinical practice in a Netherlands-based academic hospital.
Among pediatric patients with cerebral venous thrombosis, treatment with rivaroxaban or standard anticoagulants resulted in a similarly reduced risk for recurrent VTE or bleeding.
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
Researchers from the Medical University of Vienna highlight diagnostic and management strategies for the treatment of cyclic thrombocytopenia.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
A 2-fold increase in mortality was seen among patients with thrombotic thrombocytopenic purpura compared with the general US population.
Study results confirmed that dabigatran has comparable efficacy and safety as standard of care heparin or vitamin K antagonists for acute VTE in children.
With close monitoring, the discontinuation of eculizumab is safe in the majority of patients with atypical hemolytic uremic syndrome.
A novel diagnostic algorithm was able to safely rule out DVT in patients visiting an emergency department, thereby reducing the need for ultrasound imaging.
A team of investigators examined the effect of a history of venous thromboembolism on recurrence of thrombosis in patients with cancer.
A retrospective analysis showed similar outcomes for cyclophosphamide as seen with rituximab in treatment of immune thrombotic thrombocytopenic purpura.
A retrospective analysis shows that real-world outcomes with caplacizumab for thrombotic thrombocytopenic purpura are similar to clinical trial results.
In minor procedures, coagulation differences may not be clinically significant to determine bleeding or thrombotic periprocedure complication risks.
Patients with thrombophilia demonstrate an elevated risk for venous thromboembolism after undergoing orthopedic surgery.
Caplacizumab with therapeutic plasma exchange and immunosuppression appears to prevent unfavorable clinical outcomes in patients with immune-mediated TTP.
Survey results suggest significant alignment among patients and physicians about symptom burden of ITP, but not frequency or severity of fatigue.
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
Prothrombotic autoantibodies, similar to those with antiphospholipid syndrome, appear to be elevated in hospitalized patients with COVID-19.
A pair of researchers discuss the treatment and specific clinical challenges associated with thrombotic thrombocytopenic purpura in women who are pregnant.
In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.
Hospitalized patients with elevated Sdc-1 levels have a higher risk for death in patients with iTTP. Levels may be used for risk stratification.
New research has not found RBC transfusion to be an independent risk factor for venous or arterial thrombosis in hospitalized patients.
Investigators compared first-line dexamethasone with prednisone on admission and readmission rates among patients with acute immune thrombocytopenia.
A single-center study in Canada found a point prevalence of Gaucher disease of 0.5% among Canadian patients referred to a hematologist for thrombocytopenia.
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
A team of researchers evaluated the current health system-wide practices and protocols associated with the administration of DOACs in anticoagulation clinics.
The American Society of Hematology released evidence-based guidelines for the treatment of DVT and PE in patients without cancer.
Cerebral MRI data suggest that neurological symptoms and cognitive impairment may be common among patients with an acute TTP event.
A DOAC population-based management tool may help determine and address potential interactions between DOACs and NSAIDs in patients receiving both treatments.
Patients with sickle cell disease may have an increased risk for venous thromboembolic events, especially pulmonary embolism, following surgical splenectomy.
A novel optical sensor accurately measures anticoagulation and global hemostasis in patients during cardiac surgery with cardiopulmonary bypass.
Study results suggest that TEG and turbidimetry measure clot formation in separate ways and should be used synergistically.
Researchers reported a safe and effective treatment strategy to prevent clot progression in neonates and children with catheter-related arterial thrombosis.
Despite existing guidelines, patients with first-time acute DVT or PE were administered unfractionated heparin more frequently than LMWH.
In a comprehensive evaluation, investigators assessed the efficacy and safety of 4F-PCC for oral fXa inhibitor–related emergent bleeding.
Thrombotic thrombocytopenic purpura (TTP) related to systemic lupus erythematosus may not cause worse outcomes compared with primary immune-mediated TTP.
A team of investigators evaluated knowledge gaps among patients with TTP in remission and found a range of levels of understanding of the condition.
TTP is a rare disease that clinicians may not often treat; however, it is important to be aware of new developments for the treatment of this patient population.
In patients hospitalized with COVID-19, thrombi in segmental pulmonary arteries are common and are located in opacitated lung segments, which may suggest local clot formation.
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
A position paper recently published by the National Pulmonary Embolism Response Team outlines an approach for diagnosing and treating pulmonary embolism in patients with COVID-19.
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.
Eltrombopag may be an effective alternative to intravenous immunoglobulin for the perioperative treatment of immune thrombocytopenia.
Investigators assess underlying mechanisms and relevant biomarkers of morbidity and mortality due to coagulopathy in patients with severe COVID-19 infection.
Inadvertent administration may result in serious adverse events.
Increases in the incidence of CVT from 2006 to 2016 driven mainly by increases among men, older women.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
As PKD directly affects the catalysis of substrates and products involved in the production of ATP, the glycolytic pathway is compromised, thus leading to several cellular defects.